Johnson & Johnson’s $55bn bet: What it means for healthcare and investors
Johnson & Johnson is investing $55 billion in U.S. manufacturing, R&D, and technology, reinforcing its leadership in pharmaceuticals. Find out more. Read More
Elevation Oncology strengthens cancer drug pipeline as cash reserves hit $93m
Elevation Oncology, Inc. has released its financial results for the fourth quarter and full-year 2024, outlining significant progress in its pipeline of targeted cancer therapies. ... Read More
Akeso completes patient enrollment for Phase III Cadonilimab trial in high-risk HCC
Akeso, Inc. has announced the completion of patient enrollment for its Phase III cadonilimab trial (COMPASSION-22/AK104-306), marking a significant milestone in the clinical development of ... Read More
PAVmed secures $2.4m to advance Veris Health’s implantable cancer monitoring technology
PAVmed Inc., a diversified commercial-stage medical technology company, has completed a $2.37 million private placement financing, reinforcing its investment in Veris Health Inc., a majority-owned ... Read More
KKR takes controlling stake in India’s cancer care giant Healthcare Global Enterprises in $400m deal
In a landmark deal set to transform India's oncology landscape, KKR, a global investment giant, has signed definitive agreements to acquire a controlling stake in ... Read More
Moleculin Biotech moves forward with pivotal Annamycin trial in AML after FDA backing
Moleculin Biotech, Inc. (Nasdaq: MBRX), a late-stage pharmaceutical company focused on developing innovative treatments for acute myeloid leukemia, has received critical guidance from the U.S. ... Read More
Akeso begins Phase 3 trial of cadonilimab as consolidation therapy for non-small cell lung cancer
Akeso, Inc. (9926.HK) has initiated its pivotal Phase 3 cadonilimab trial for non-small cell lung cancer (NSCLC), marking a significant advancement in immunotherapy research. The ... Read More
AbbVie reports 2024 financial results: Revenue growth driven by immunology and neuroscience
AbbVie (NYSE: ABBV) has released its full-year and fourth-quarter 2024 financial results, showing continued revenue growth despite challenges such as the U.S. loss of exclusivity ... Read More
ImmunityBio, BeiGene launch Phase 3 Trial to advance lung cancer immunotherapy
ImmunityBio, Inc. (NASDAQ: IBRX) has entered into a collaboration and supply agreement with BeiGene, Ltd., a global oncology company, to initiate a confirmatory Phase 3 ... Read More
Tempus AI stock soars 14% after FDA approval of xT CDx test
Tempus AI, a leader in healthcare technology, has unveiled its FDA-approved in vitro diagnostic device, xT CDx, marking a pivotal step forward in precision oncology. ... Read More